Daniel Vitt

1.2k total citations
45 papers, 906 citations indexed

About

Daniel Vitt is a scholar working on Molecular Biology, Epidemiology and Immunology. According to data from OpenAlex, Daniel Vitt has authored 45 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 8 papers in Epidemiology and 8 papers in Immunology. Recurrent topics in Daniel Vitt's work include Biochemical and Molecular Research (8 papers), Axial and Atropisomeric Chirality Synthesis (5 papers) and Cytomegalovirus and herpesvirus research (5 papers). Daniel Vitt is often cited by papers focused on Biochemical and Molecular Research (8 papers), Axial and Atropisomeric Chirality Synthesis (5 papers) and Cytomegalovirus and herpesvirus research (5 papers). Daniel Vitt collaborates with scholars based in Germany, United States and Australia. Daniel Vitt's co-authors include Gerhard Bringmann, Johann Leban, Hella Kohlhof, Ralf Stowasser, Kristina Wolf, Markus H. J. Seifert, Stefan Strobl, Evelyn Peelen, Mirko Zaja and Joachim Bischof and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Daniel Vitt

42 papers receiving 884 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Vitt Germany 20 435 205 168 137 122 45 906
Song Feng China 17 359 0.8× 170 0.8× 159 0.9× 135 1.0× 90 0.7× 38 944
Christos Papageorgiou Greece 16 451 1.0× 83 0.4× 202 1.2× 172 1.3× 71 0.6× 61 1.0k
Linda F. Epstein United States 15 518 1.2× 313 1.5× 130 0.8× 91 0.7× 111 0.9× 23 1.2k
Nathan A. Lack Türkiye 22 668 1.5× 128 0.6× 124 0.7× 169 1.2× 218 1.8× 55 1.4k
Naoyuki G. Saito United States 13 583 1.3× 70 0.3× 110 0.7× 239 1.7× 79 0.6× 32 1.0k
Francesco Turrini Italy 20 376 0.9× 98 0.5× 40 0.2× 94 0.7× 131 1.1× 56 1.3k
Caly Chien United States 18 241 0.6× 496 2.4× 82 0.5× 181 1.3× 151 1.2× 36 1.5k
Colin Stubberfield United Kingdom 19 749 1.7× 106 0.5× 284 1.7× 419 3.1× 199 1.6× 30 1.4k
Abhinav Kumar United Kingdom 14 423 1.0× 114 0.6× 79 0.5× 109 0.8× 47 0.4× 38 791
Patrick Brassil United States 18 548 1.3× 61 0.3× 214 1.3× 272 2.0× 210 1.7× 28 1.2k

Countries citing papers authored by Daniel Vitt

Since Specialization
Citations

This map shows the geographic impact of Daniel Vitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Vitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Vitt more than expected).

Fields of papers citing papers by Daniel Vitt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Vitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Vitt. The network helps show where Daniel Vitt may publish in the future.

Co-authorship network of co-authors of Daniel Vitt

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Vitt. A scholar is included among the top collaborators of Daniel Vitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Vitt. Daniel Vitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stiller, Tracey, Christian Gege, Wael Saeb, et al.. (2025). Carboxylic Acid Bioisosteres Boost Nurr1 Agonist Selectivity. Journal of Medicinal Chemistry. 68(15). 16212–16226. 1 indexed citations
2.
Schreieck, Amelie, Evelyn Peelen, João Quinta da Fonseca, et al.. (2025). DOP012 Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical study. Journal of Crohn s and Colitis. 19(Supplement_1). i106–i106.
3.
4.
Gege, Christian, Friedrich Hahn, Christina Wangen, et al.. (2024). Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity. ChemMedChem. 19(19). e202400292–e202400292. 5 indexed citations
5.
6.
Polasek, Thomas M., et al.. (2023). EP63 FIRST IN HUMAN TRIAL OF IMU-856, AN ORALLY AVAILABLE REGULATOR OF BARRIER FUNCTION FOR THE TREATMENT OF CELIAC DISEASE. Gastroenterology. 164(6). S–1204. 2 indexed citations
7.
Wangen, Christina, Julia Tillmanns, Christian Gege, et al.. (2023). Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels. Antiviral Research. 221. 105769–105769. 1 indexed citations
8.
Vehreschild, Maria J. G. T., P.A. Atanasov, Cristian Oancea, et al.. (2022). Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infectious Diseases and Therapy. 11(6). 2159–2176. 8 indexed citations
9.
Kim, Yu-Jin, Beatrice Cubitt, Yíngyún Caì, et al.. (2020). Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro. Viruses. 12(8). 821–821. 6 indexed citations
10.
Kohlhof, Hella, et al.. (2020). Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. World Journal of Gastrointestinal Pathophysiology. 11(6). 114–130. 18 indexed citations
11.
Kohlhof, Hella, et al.. (2020). Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics. 45(5). 557–573. 22 indexed citations
12.
Peelen, Evelyn, et al.. (2020). Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 43. 102129–102129. 46 indexed citations
13.
14.
Gruber, Wolfgang, Christina Sternberg, Sonia Coni, et al.. (2017). Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance. International Journal of Cancer. 142(5). 968–975. 39 indexed citations
15.
Hutterer, Corina, Jens Milbradt, Stuart T. Hamilton, et al.. (2017). Inhibitors of dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) exert a strong anti-herpesviral activity. Antiviral Research. 143. 113–121. 32 indexed citations
16.
Gruber, Wolfgang, Christina Sternberg, Mirko Zaja, et al.. (2016). DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance. Oncotarget. 7(6). 7134–7148. 55 indexed citations
17.
Haasbach, Emanuel, Sarah J. Reiling, Christina Ehrhardt, et al.. (2013). The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus. Antiviral Research. 99(3). 336–344. 37 indexed citations
18.
Marschall, Manfred, Karin Kosulin, Sabrina Wagner, et al.. (2013). Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. Antiviral Research. 100(3). 640–648. 39 indexed citations
19.
Lang, Martin, Markus H. J. Seifert, Kristina Wolf, et al.. (2011). Discovery and hit-to-lead optimization of novel allosteric glucokinase activators. Bioorganic & Medicinal Chemistry Letters. 21(18). 5417–5422. 15 indexed citations
20.
Leban, Johann & Daniel Vitt. (2011). Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases. Arzneimittelforschung. 61(1). 66–72. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Song Feng Breakdown of academic impact, for papers by Christos Papageorgiou Breakdown of academic impact, for papers by Linda F. Epstein Breakdown of academic impact, for papers by Nathan A. Lack Breakdown of academic impact, for papers by Naoyuki G. Saito Breakdown of academic impact, for papers by Francesco Turrini Breakdown of academic impact, for papers by Caly Chien Breakdown of academic impact, for papers by Colin Stubberfield Breakdown of academic impact, for papers by Abhinav Kumar Breakdown of academic impact, for papers by Patrick Brassil
Rankless by CCL
2026